Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight.

Waldemar E WysokinskiDavid A FroehlingDamon E HoughtonRobert D McBane Ii Danielle T VlaznyDalene M Bott-KitslaarWiktoria KuczmikKarolina SutkowskaKaja BatorDavid O HodgeLisa G PetersonAna I Casanegra

Published in: European journal of haematology (2020)

Treatment of acute VTE is associated with a higher incidence of bleeding in patients with bodyweight <60 kg. A higher VTE recurrence rate occurred only in cancer patients with bodyweight >120 kg on rivaroxaban.

Keyphrases

venous thromboembolism
liver failure
direct oral anticoagulants
respiratory failure
drug induced
aortic dissection
papillary thyroid
atrial fibrillation
risk factors
stem cells
combination therapy
intensive care unit
young adults
mechanical ventilation